Imetelstat, Targeting Telomerase
from OncoPharm Hosted by John Bossaer
A new drug is approved for MDS. While some will likely benefit from this new agent, the more enticing news is that inhibiting telomerase may be an attractive target for many malignancies.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 12 minutes long.
When was this OncoPharm episode published?
This episode was published on June 13, 2024.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.